AngioDynamics Introduces OMNIFLEX 15MM BILIARY STENT.

Business Editors, Health/Medical Writers

QUEENSBURY, N.Y.--(BW HealthWire)--May 7, 2001

AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc. (Amex: EZM.A and EZM.B) announced today that it will initiate marketing of its new OMNIFLEX(TM)15MM BILIARY STENT in the United States.

This new product line features a balloon-expandable stent system with a low profile platinum stent that provides a unique combination of visibility, flexibility, and radial strength. Unlike stents constructed of stainless steel or nitinol, which contain nickel, the platinum construction of the OMNIFLEX offers no potential allergic response to nickel. The OMNIFLEX(TM) 15MM BILIARY STENT has virtually no foreshortening upon initial deployment, which aided by the stent's visibility, allows for accurate placement.

The OMNIFLEX(TM) 15MM BILIARY STENT is Magnetic Resonance Angiography (MRA) compatible due to its platinum material and design characteristics. The platinum OMNIFLEX(TM) is nonferromagnetic, which has been shown to produce significantly less artifacts than stainless steel or nitinol stents during MRA procedures. Artifacts can reduce the visibility of the lumen and make accurate assessment of the patency of that lumen more difficult.

The OMNIFLEX(TM) 15MM BILIARY STENT is pre-mounted on the AngioDynamics(R) WORKHORSE(TM) PTA catheter which features a high-pressure, non-compliant balloon that is ideal for the OMNIFLEX(TM) 15MM delivery system. The OMNIFLEX(TM) 15MM BILIARY STENT system is available in 5mm, 6mm, 7mm, and 8mm stent diameters.

Commenting on the announcement, Eamonn P. Hobbs, President and CEO of AngioDynamics, said, "Adding this new product to the Company's well-recognized portfolio of angiographic catheters, thrombolytic drug delivery systems, electro-mechanical injectors, vascular access devices and carbon dioxide systems, helps place AngioDynamics as a full-service provider to the global Interventional Radiology community."

E-Z-EM, the world's largest manufacturer of contrast agents for gastrointestinal radiology, has developed the only CT injector on the market that can help detect contrast extravasation, the PercuPump(R) with patented EDA(TM) technology. The Company's wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, including angiographic, thrombolytic, vascular access, and drainage products, as well as stents and medical devices for angioplasty. Enteric Products, Inc., another subsidiary, develops, manufactures and markets tests for detection of the ulcer-causing bacterium Helicobacter pylori. For additional information, please contact Frank Kerrigon at 1-800-544-4624, ext. 325, (E-mail: [e-mail]) or visit our corporate web site at www.ezem.com.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, general market conditions, competition and pricing, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended March 3, 2001,as well as its Annual Report on Form 10-K for the year ended June 3, 2000, may affect the actual results achieved by the Company.